Cisplatin

Every second cancer therapy uses active ingredients containing platinum, resulting in an annual market demand of roughly 2 tons of platinum – a demand that is strongly increasing. If only primary materials are used to meet this demand, the platinum alone would account for more than 63,000 tons of CO2e per ...

Heraeus Precious Metals business line Pharmaceutical Ingredients provides a wide range of active pharmaceutical ingredients, which includes Oxaliplatin. Contact us for more information.

Heraeus Precious Metals business line Pharmaceutical Ingredients provides a wide range of active pharmaceutical ingredients, which includes Carboplatin. Contact us for more information.

Heraeus Precious Metals business line Pharmaceutical Ingredients provides a wide range of active pharmaceutical ingredients, which includes Bendamustine hydrochloride monohydrate. Contact us for more information.

Heraeus Precious Metals offers a wide range of homogeneous and heterogeneous precious metal catalysts, enabling numerous chemical reactions. Contact us for more information.

Heraeus Precious Metals business line Pharmaceutical Ingredients provides a wide range of active pharmaceutical ingredients, which includes Thiotepa. Contact us for more information.

Heraeus Precious Metals business line Pharmaceutical Ingredients provides a wide range of active pharmaceutical ingredients which includes Aresenic. Contact us for more information.

We support our customers in the exclusive synthesis of cytotoxic compounds from the research stage to registration to market launch. With these comprehensive services, our customers are free to focus on their core business and transform their innovative ideas into commercial products.

Franziska Heck and Artur Gantarev of Heraeus Precious Metals discuss the development of precious metal-based carbon microspheres catalysts for the pharma industry.

Heraeus Precious Metals specializes in manufacturing of generic highly potent active pharmaceutical ingredients (HPAPIs) with a focus on platinum-based HPAPIs for cancer treatment. We have been US-FDA-approved for over 35 years, maintaining an exceptional track record with major health agencies worldwide. Our commitment to excellence has secured us a prominent global position in the supply of high-quality HPAPIs, reflecting our dedication to improving patient outcomes.